-THIS IS A RED INK STAMP-
I certify this to be a true and exact copy of the original document on file with the Ohio State Board of Pharmacy.
Steven W. Schierholt, Esq., Executive Dir.
Date: 3/3/2026
-MUST HAVE BOARD SEAL TO BE OFFICIAL-

SUMMARY SUSPENSION/NOTICE OF OPPORTUNITY FOR HEARING
TERMINAL DISTRIBUTOR OF DANGEROUS DRUGS LICENSE

IN THE MATTER OF: **CASE NO. A-2026-0059**

Restore Medical LLC DBA Restore Medical **License No. 02-60001451**
c/o Kelly Michelle Hriesik, CNP
990 Lexington Ave.
Mansfield, OH 44907

March 3, 2026

Dear Restore Medical and CNP Hriesik:

You are hereby notified, in accordance with Section 119.07 of the Ohio Revised Code (ORC), the Ohio Board of Pharmacy (Board) hereby SUMMARILY SUSPENDS Restore Medical's license as a Terminal Distributor of Dangerous Drugs (TDDD) under authority of Sections 4729.57 and 4729.571 of the Ohio Revised Code.

Furthermore, the Board finds that based upon the facts set forth in the Allegations Section, there is clear and convincing evidence of a danger of immediate and serious harm to others due to Restore Medical's method used to possess or distribute dangerous drugs. As such, the Board summarily suspends Restore Medical's license as a Terminal Distributor of Dangerous Drugs.

JURISDICTION

1. Pursuant to section 4729.57 of the Ohio Revised Code and the rules adopted thereunder, the Board has the authority to suspend, revoke, restrict, limit, or refuse to grant or renew any license issued pursuant to Sections 4729.54 and 4729.55 of the ORC to practice as a TDDD in the state of Ohio. Further, pursuant to Section 4729.55(E), the Board shall refuse to issue a future license to an applicant for a TDDD if the applicant, or any agent (including any owner or responsible person) or employee of the applicant, has been found to have violated any of the specified laws identified therein or any rule of the board, absent proof of adequate safeguards assuring prevention of a recurrence of the violation. Additionally, Section 4729.57 of the Ohio Revised Code grants the Board the authority to impose a monetary penalty or forfeiture not to exceed in severity any fine designated under the Revised Code for a similar offense or $1,000 if the acts committed have not been classified as an offense by the ORC.

2. Pursuant to Section 4729.571(A)(1) of the ORC and the rules adopted thereunder, the Board has the authority to suspend a terminal distributor's license without a hearing if it determines that there is

clear and convincing evidence of a danger of immediate and serious harm to others due to the method used by the terminal distributor to possess or distribute dangerous drugs

3. Restore Medical LLC DBA Restore Medical, located at 990 Lexington Ave., Mansfield, OH 44907, is a clinic licensed by the Board (TDDD 02-60001451). The clinic is owned by Dr. Jeffrey Zaika [Ohio Chiropractic Board No. DC-01870] and lists Kelly Michelle Hriesik, APRN [Ohio Board of Nursing License No. APRN.CNP.024106] as the Responsible Person.

ALLEGATIONS

1. On or about February 25, 2026, the Board conducted an inspection at Restore Medical ("Restore"). Responsible Person Certified Nurse Practitioner (CNP) Kelly Hriesik was present during the inspection.

2. During the inspection, the following unapproved dangerous drugs, intended for injection, were located in the clinic's active drug stock. The drugs were obtained from an unknown source and displayed Korean writing on the labels:

    a. One box containing #10 vials, labeled Luthione 1200mg. The box displayed Korean writing and the manufacturer was Daehan Nupharm, which is an entity that is not a licensed wholesale drug distributor, outsourcing facility, compounding pharmacy, or drug manufacturer in the United States and does not have Food and Drug Administration (FDA) manufacturer registration;

    b. #323 vials, labeled vitamin C, Korean manufacturer Daehan Nupharm;

    c. #9 vials, labeled in Korean as vitamin B-12.

3. Board Agents spoke with CNP Hriseik:

    a. During the inspection, CNP Hriseik initially claimed to not have the key to the cabinet that was later found to contain #300 vials of Korean vitamin C.

    b. CNP Hriseik stated she did not remember where she had purchased the Korean drugs and could produce no records of their purchase.

    c. She denied administering any of the non-FDA approved drugs to patients but stated she gave at least one of the chiropractors who work in the office (Dr. Zaita) an infusion of non-FDA approved vitamin C.

4. The inspection resulted in warnings requiring written responses for violations including the following:

    a. The clinic purchased foreign drugs from an unknown source and the clinic was not conducting license verification.

b. Multiple dangerous drugs and controlled substances in the active stock were expired or adulterated. At least one product expired in 2024, and expired products were not stored in a separate and secure area away from drugs intended for patient administration.

c. The clinic does not have a process in place to destroy controlled substances or expired drug products and has no destruction records.

d. No controlled substance inventories were conducted.

e. The clinic does not have a written drug recall procedure.

f. The active drug stuck contained single-dose vials being used as multi-dose vials.

g. Numerous multi-use vials were found open/punctured in the active drug stock and were not dated with the initial date of puncture or a 28-day beyond use date.

h. The clinic failed to maintain complete records of administration and/or compounded records.

   i. Records did not contain the drug strength, dosage form, or quantity administered.

   ii. At least one record did not contain the identification of the prescriber/person giving the administration.

POTENTIAL VIOLATIONS OF LAW

1. Such conduct as set forth in the Allegations Section, if proven, each constitutes a violation of section 3715.52(A) of the ORC, Prohibited acts, each, a misdemeanor of the fourth degree, each punishable by a maximum penalty of $2,000 if committed by an organization: The following acts and causing them are prohibited:

   a. The manufacture, sale, or delivery, holding or offering for sale of any food, drug, device, or cosmetic that is adulterated[1] or misbranded,[2] ORC Section 3715.52(A)(1); and/or

   b. The adulteration or misbranding of any food, drug, device, or cosmetic, ORC Section 3715.52(A)(2); and/or

   c. The receipt in commerce of any food, drug, device, or cosmetic that is adulterated or misbranded, and the delivery or proffered delivery thereof for pay or otherwise, ORC Section 3715.52(A)(3).

2. Such conduct as set forth in the Allegations Section, if proven, each constitutes a violation of Section 4729.51(F) of the ORC, effective April 9, 2025, Selling, purchasing, distributing, or delivering dangerous or investigational drugs – No licensed terminal distributor of dangerous drugs or person

[1] ORC Section 3715.63 – When drug or device is adulterated.
[2] ORC Section 3715.64 – Misbranded drug or device.

that is exempt from licensure under section 4729.541 of the Revised Code shall purchase dangerous drugs or investigational drugs or products from any person other than a licensed manufacturer, outsourcing facility, third-party logistics provider, repackager, or wholesale distributor, punishable by a maximum penalty of $5,000 if committed by an organization.

3. Such conduct as set forth in the Allegations Section, if proven, each constitutes a violation of Section 4729.60(B) of the ORC, Verification of license prior to transactions – Before a licensed terminal distributor of dangerous drugs may purchase dangerous drugs at wholesale, the terminal distributor shall query the roster established pursuant to section 4729.59 of the Revised Code to confirm the seller is licensed to engage in the sale or distribution of dangerous drugs at wholesale, each violation punishable by a maximum penalty of $1,000 if committed by an organization.

4. Such conduct as set forth in the Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-3-04 of the OAC, as effective March 1, 2019, Verification of licensure prior to sale or purchase, each violation punishable by a maximum penalty of $1,000:

    a. Before a terminal distributor of dangerous drugs may purchase dangerous drugs at wholesale, the terminal distributor shall query the board's online roster (available on the board's website: www.pharmacy.ohio.gov) to confirm any of the following:

        i. The seller is licensed to engage in the sale of dangerous drugs in accordance with section 4729.52 of the Revised Code, OAC Rule 4729:5-3-04(A)(1); and/or

        ii. The seller is licensed to engage in the occasional sale or distribution of dangerous drugs at wholesale in accordance with rule 4729:5-3-09 of the Administrative Code, OAC Rule 4729:5-3-04(A)(2); and/or

    b. If no documented query is conducted before a purchase is made, it shall be presumed that the purchase of dangerous drugs by the terminal distributor is in violation of section 4729.51 of the Revised Code, OAC Rule 4729:5-3-04(B).

5. Such conduct as set forth in the Allegations Section, if proven, constitutes a violation of the following divisions of Rule 4729:5-3-06 of the OAC, as effective March 1, 2019, Storage of adulterated drugs, each violation punishable by a maximum penalty of $1,000:

    a. To prevent their use, adulterated drugs, as defined in agency 4729 of the Administrative Code, shall be stored in a separate and secure area apart from the storage of drugs used for dispensing, personally furnishing, compounding and administration, OAC 4729:5-3-06; and/or

        i. Adulterated drugs shall be stored no longer than one year from the date of adulteration or expiration by those holding a terminal distributor of dangerous drugs license. Adulterated drugs shall be stored in a manner that prohibits access by unauthorized persons, OAC 4729:5-3-06(A); and/or

        ii. Dangerous drugs, other than controlled substances, may be destroyed utilizing proper methods of disposal and following the record keeping requirements noted in agency 4729

of the Administrative Code, or may be donated to a pharmacy school pursuant to sections 3715.88 to 3715.92 of the Revised Code. Methods of disposal of non-controlled dangerous drugs shall prevent the possession or use of the drugs by unauthorized persons, OAC Rule 4729:5-3-06(B); and/or

iii. Dangerous drugs that are controlled substances shall be disposed of pursuant to rule 4729:5-3-01 of the Administrative Code, OAC 4729:5-3-06(C).

6. Such conduct as set forth in the Allegations Section, if proven, constitutes a violation of the following divisions of Rule 4729:5-3-07 of the OAC, as effective March 1, 2019, Controlled substance inventory requirements, each violation punishable by a maximum penalty of $1,000:

   a. Unless otherwise stated in this division of the Administrative Code, all category III terminal distributor licensees shall complete a controlled substances inventory in accordance with 21 CFR 1304.11 (9/9/2014), OAC Rule 4729:5-3-07(A); and/or

   b. All controlled substance inventories performed in accordance with this rule shall be conducted on an annual basis. The annual inventory may be taken on any date which is within thirteen months of the previous inventory date, OAC Rule 4729:5-3-07(B); and/or

   c. The terminal distributor's responsible person shall be responsible for completing and maintaining this inventory record at the location licensed as a terminal distributor of dangerous drugs, OAC Rule 4729:5-3-07(C); and/or

   d. All inventory records shall be maintained for a period of three years from the completion date of the inventory and made readily retrievable, OAC Rule 4729:5-3-07(D).

7. Such conduct as set forth in the Allegations Section, if proven, constitutes a violation of the following divisions of Rule 4729:5-5-24 of the OAC, as effective August 19, 2022, Drug inventory records and other record keeping provisions, each violation punishable by a maximum penalty of $1,000:

   a. Records of receipt shall contain the name, strength, dosage form, and quantity of the dangerous drugs received, the name and address of the seller, the name and address of the recipient, and the date of receipt, OAC Rule 4729:5-5-24(A); and/or

   b. Records of dangerous drugs disposed from inventory, other than controlled substances, shall contain the name, strength, dosage form, and quantity of the dangerous drug disposed, the date of disposal, the method of disposal, and the positive identification of the licensed or registered health care professional that performed the disposal, OAC Rule 4729:5-5-24(C); and/or

   c. Records of controlled substance drug disposal shall comply with the requirements of rule 4729:5-3-01 of the Administrative Code, OAC Rule 4729:5-5-24(D); and/or

   d. Controlled substance inventory records shall be maintained in accordance with rule 4729:5-3-07 of the Administrative Code, OAC Rule 4729:5-5-24(J).

8. Such conduct as set forth in the Allegations Section, if proven, constitutes a violation of the following divisions of Rule 4729:5-3-01 of the OAC, as effective July 1, 2024, Disposal of controlled substances, each violation punishable by a maximum penalty of $1,000:

    a. A terminal distributor of dangerous drugs shall dispose of controlled substance dangerous drugs in accordance with 21 C.F.R. 1317 (9/25/2023). The method of destruction must render the controlled substances to a state of non-retrievable. Records of controlled substance destruction that are required pursuant to 21 C.F.R. 1304 (9/25/2023) shall be maintained for a minimum of three years and made readily retrievable, OAC Rule 4729:5-3-01(B).

9. Such conduct as set forth in the Allegations Section, if proven, constitutes a violation of the following divisions of Rule 4729:5-3-18 of the OAC, as effective November 11, 2024, Dangerous drug recall procedures, each violation punishable by a maximum penalty of $1,000:

    a. A terminal distributor of dangerous drugs shall develop and implement a written procedure for the management of recalls by the manufacturer for dangerous drugs stocked by the terminal distributor. Such procedures shall include, where appropriate, contacting patients to whom the recalled drug products have been dispensed or personally furnished, OAC Rule 4729:5-3-18(A).

10. Such conduct as set forth in Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-19-03 of the OAC, as effective February 4, 2021, Security, control and storage of dangerous drugs, each violation punishable by a maximum penalty of $1,000:

    a. The security and control of dangerous drugs is the responsibility of the responsible person on the terminal distributor of dangerous drugs license and the terminal distributor of dangerous drugs, OAC Rule 4729:5-19-03(A); and/or

    b. Upon the initial puncture of a multiple-dose vial containing a drug, the vial shall be labeled with a beyond-use date or date opened. The beyond-use date for an opened or entered (e.g., needle punctured) multiple-dose container with antimicrobial preservatives is twenty-eight days, unless otherwise specified by the manufacturer. A multiple-dose vial that exceeds its beyond-use date shall be deemed adulterated, OAC Rule 4729:5-19-03(L); and/or

    c. Adulterated drugs, including expired drugs, shall be stored in accordance with rule 4729:5-3-06 of the Administrative Code, OAC Rule 4729:5-19-03(M); and/or

    d. Disposal of controlled substances shall be conducted in accordance with rule 4729:5-3-01 of the Administrative Code, OAC Rule 4729:5-19-03(N); and/or

    e. Disposal of non-controlled dangerous drugs shall be conducted in accordance with rule 4729:5-3-06 of the Administrative Code, OAC Rule 4729:5-19-03(O).

11. Such conduct as set forth in Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-3-14(A) of the OAC, as effective March 1, 2020, General security requirements, each violation punishable by a maximum penalty of $1,000:

a. All terminal distributors of dangerous drugs shall provide effective controls and procedures to ensure supervision and control of dangerous drugs, as required in division (B) of section 4729.55 of the Revised Code, and adequate safeguards to ensure that dangerous drugs are being distributed in accordance with all state and federal laws, as required in section 4729.55 of the Revised Code, OAC Rule 4729:5-3-14(A)(2).

12. Such conduct as set forth in Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-19-04 of the OAC, Record Keeping, as effective March 1, 2020, each violation punishable by a maximum penalty of $1,000:

    a. A clinic or prescriber office shall keep a record of all dangerous drugs received, administered, personally furnished, disposed, sold or transferred, OAC Rule 4729:5-19- 04(A); and/or

    b. Records of receipt shall contain the name, strength, dosage form, and quantity of the dangerous drugs received, the name and address of the seller, the name and address of the recipient, and the date of receipt. An invoice from a drug distributor licensed in accordance with division 4729:6 of the Administrative Code containing the required information may be used to meet this requirement, OAC Rule 4729:5-19-04(B); and/or

    c. Records of administration shall contain the name, strength, dosage form, and quantity of the dangerous drugs administered, the name and date of birth of the person to whom or for whose use the dangerous drugs were administered, the date of administration and for non-controlled substance dangerous drugs: the identification of the health care professional administering the drug. * * *, OAC Rule 4729:5-19-04(E)(1)(a); and/or

    d. Records of dangerous drugs administered which become a permanent part of the patient's medical record shall be deemed to meet the requirements of this paragraph, OAC Rule 4729:5-19-04(E)(2); and/or

    e. Records of dangerous drugs administered by a health care professional, acting within the professional's scope of practice, who is not a prescriber shall include documentation of an order issued by a prescriber or protocol authorizing the administration of the drug. An order that is a permanent part of the patient's medical record shall be deemed to meet the requirements of this paragraph. Orders for the administration of controlled substances shall be documented using positive identification, OAC Rule 4729:5-19-04(E)(3); and/or

    f. Records of disposal of dangerous drugs from inventory, other than controlled substances, shall contain the name, strength, dosage form, and quantity of the dangerous drug disposed, the date of disposal, the method of disposal, and the identification of the licensed health care professional that performed the disposal, OAC Rule 4729:5-19-04(F); and/or

    g. All records maintained in accordance with this rule and rule 4729:5-19-03 of the Administrative Code shall be readily retrievable and shall be kept on-site for a period of three years, OAC Rule 4729:5-19-04(J).

13. Such conduct as set forth in the Allegations Section, if proven, constitutes a violation of the following sections of Rule 4729:7-3-06 of the OAC, as effective March 31, 2021, Record Keeping, each violation punishable by a maximum penalty of $1,000:

    a. The responsible person shall maintain the following records relating to the compounding of dangerous drugs:

        i. All drug orders and records, including logs, relating to the compounding of drugs. Such drug orders and records may be retained by any process providing an exact duplicate of the original order or prescription, OAC Rule 4729:7-3-06(A)(1); and/or

        ii. Records of each drug compounded shall, at a minimum, include all the following:

            1. The full name of the patient, unless compounded in accordance with paragraph (G)(2) of rule 4729:7-3-04 of the Administrative Code, OAC Rule 4729:7-3-06(A)(3)(a); and/or

            2. Name, strength, and dosage form of the compounded drug, OAC Rule 4729:7-3-06(A)(3)(b); and/or

            3. Name and quantity of each ingredient, OAC Rule 4729:7-3-06(A)(3)(c); and/or

            4. If a controlled substance, the disposition of unused drug(s) and amount, OAC Rule 4729:7-3-06(A)(3)(d); and/or

            5. Date and time of preparation, OAC Rule 4729:7-3-06(A)(3)(e); and/or

            6. Beyond-use date of the compounded drug, OAC Rule 4729:7-3-06(A)(3)(f); and/or

            7. The positive identification of the personnel responsible for compounding the drug, OAC Rule 4729:7-3-06(A)(3)(g); and/or

            8. The positive identification of either of the following:

                a. Person or persons performing medication validation prior to the compounded drug being administered, OAC Rule 4729:7-3-06(A)(3)(h)(i); and/or

                b. The prescriber personally furnishing the compounded drug, OAC Rule 4729:7-3-06(A)(3)(h)(ii).

14. Such conduct as set forth in the Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-2-01 of the OAC, Responsible person – terminal distributor, as effective April 25, 2022, each punishable by a maximum penalty of $1,000:

    a. The responsible person to whom the terminal distributor of dangerous drugs license has been issued and all licensed health professionals on duty are responsible for compliance with all state

and federal laws, regulations, and rules governing the distribution of dangerous drugs, OAC Rule 4729:5-2-01(E)(4); and/or

b. The responsible person shall be responsible for ensuring the terminal distributor of dangerous drugs requirements are met, including, but not limited to, the supervision and control of dangerous drugs as required in division (B) of section 4729.55 of the Revised Code, adequate safeguards as required in division (C) of section 4729.55 of the Revised Code, security and control of dangerous drugs and maintaining all drug records otherwise required, OAC Rule 4729:5-2-01(E)(6).

15. Such conduct as set forth in Allegations Section, if proven, constitutes a violation of each of the following divisions of Section 4729.55 of the ORC, as effective October 3, 2023, TDDD license requirements, each violation punishable by a maximum penalty of $1,000:

    a. The applicant is equipped as to land, buildings, and equipment to properly carry on the business of a terminal distributor of dangerous drugs within the category of licensure approved by the board, ORC 4729.55(A); and/or

    b. A… licensed health professional authorized to prescribe drugs… will maintain supervision and control over the possession and custody of dangerous drugs that may be acquired by or on behalf of the applicant, ORC 4729.55(B); and/or

    c. Adequate safeguards are assured to prevent the sale or other distribution of dangerous drugs by any person other than a pharmacist or licensed health professional authorized to prescribe drugs, ORC 4729.55(C).

16. Such conduct as set forth in Allegations Section, if proven, constitutes a violation of each of the following divisions of Section 4729.57(B) of the ORC, as effective April 4, 2023, each violation punishable by a maximum penalty of $1,000:

    a. Violating any rule of the board, ORC Section 4729.57(B)(2); and/or

    b. Violating any provision of this chapter, ORC Section 4729.57(B)(3); and/or

    c. Except as provided in section 4729.89 of the Revised Code, violating any provision of the "Federal Food, Drug, and Cosmetic Act," 52 Stat. 1040 (1938), 21 U.S.C.A. 301, or Chapter 3715. of the Revised Code, ORC Section 4729.57(B)(4); and/or

    d. Ceasing to satisfy the qualifications of a terminal distributor of dangerous drugs set forth in section 4729.55 of the Revised Code, ORC Section 4729.57(B)(7); and/or

    e. Any other cause for which the board may impose discipline as set forth in rules adopted under section 4729.26 of the Revised Code, ORC Section 4729.57(B)(10).

17. Such conduct as set forth in Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-4-01 of the OAC, as effective April 25, 2022, each violation punishable by a maximum penalty of $1,000:

    a. Violating any rule of the board, OAC Rule 4729:5-4-01(B)(2); and/or

    b. Violating any provision of Chapter 4729. of the Revised Code, OAC Rule 4729:5-4-01(B)(3); and/or

    c. Except as provided in section 4729.89 of the Revised Code, violating any provision of the "Federal Food, Drug, and Cosmetic Act," 52 Stat. 1040 (1938), 21 U.S.C.A. 301, or Chapter 3715. of the Revised Code, OAC Rule 4729:5-4-01(B)(4); and/or

    d. Falsely or fraudulently promoting to the public a dangerous drug, except that nothing in this rule prohibits a terminal distributor of dangerous drugs from furnishing information concerning a dangerous drug to a health care provider or another licensed terminal distributor, OAC Rule 4729:5-4-01(B)(6); and/or

    e. Ceasing to satisfy the qualifications of a terminal distributor of dangerous drugs set forth in section 4729.55 of the Revised Code, OAC Rule 4729:5-4-01(B)(7); and/or

    f. Commission of an act that constitutes a misdemeanor that is related to, or committed in, the person's professional practice, OAC Rule 4729:5-4-01(B)(18); and/or

    g. The method used by the terminal distributor to store, possess or distribute dangerous drugs poses serious harm to others, OAC Rule 4729:5-4-01(B)(23).

YOU ARE FURTHER NOTIFIED, in accordance with the provisions of Chapters 119. and 4729. of the Ohio Revised Code, that you are entitled to a hearing before the Ohio Board of Pharmacy, if you request such a hearing within thirty (30) days of the date of the service of this notice.

IF YOU DESIRE A HEARING, such request shall either be mailed to the Ohio Board of Pharmacy, Attn: Legal, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126 or an e-mail request may be sent to legal@pharmacy.ohio.gov (**please note faxes will not be accepted**). **YOUR REQUEST MUST BE RECEIVED ON OR PRIOR TO THE 30TH DAY FOLLOWING THE SERVICE DATE OF THIS NOTICE.** Please note that if you submit a request via email, your request will be acknowledged within one business day of receipt. If you do not receive an acknowledgment, please contact the Board offices at 614-466-4143 and request the legal department. You may appear at such hearing in person, by your attorney, or by such other representative as is permitted to practice before the agency, or you may present your position, arguments or contentions in writing; and, at this hearing, you may also present evidence and examine any witnesses appearing for and against you. **If you are a business entity, including but not limited to a corporation, limited liability company, or a limited partnership, you must be represented at the hearing by an attorney licensed to practice in the state of Ohio.**

YOU ARE FURTHER ADVISED that if there is no request for such a hearing received by the Board on or prior to the 30th day following the service of this notice, the Ohio Board of Pharmacy, upon consideration of the aforementioned allegations against you, may take action without such a

hearing, and may adopt a final order that contains the board's findings. In the final order, the board may impose any of the sanctions listed in division RC 4729.57(A).

If you have questions regarding the Chapter 119. Administrative Hearing process, please e-mail your questions to legal@pharmacy.ohio.gov or call the Board office at 614-466-4143 and ask for the legal department.

BY ORDER OF THE OHIO BOARD OF PHARMACY

Steven W. Schierholt, Esq., Executive Director

SWS/zas/jrn

cc: David Geiger, Ohio Board of Nursing, at David.Geiger@nursing.ohio.gov;
Kimberly Stein, Ohio State Chiropractic Board, at Kim.Stein@chr.ohio.gov.